PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer treated with Trametinib and Hydrochloroquine.

Prior treatment

• Persisting toxicity related to prior therapy (CTCAE Grade > 1); however alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤2 AEs not constituting a safety risk based on investigator's judgment are acceptable.
• Known prior severe hypersensitivity to investigational products or any component in its formulation.
• Prior treatment with a MEK inhibitor
• Patients who are receiving any other investigational agents within 28 days before start of study treatment.
• Prior organ transplantation including allogenic stem-cell transplantation.
• Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.

Other illness

• Known history or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)
• Known history of testing positive for Human Immunodeficiency Virus (HIV) or known acquired immunodeficiency syndrome.
• Any significant disease that, in the opinion of the investigator, may impair the patient’s tolerance of study treatment.
• Active uncontrolled infection, requiring systemic therapy.

Lab values

• Severe left ventricular dysfunction as defined by ejection fraction < 45%
• Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
• Screening corrected QT interval by Fridericia (QTcF) > 500 msec
• Concurrent use of medicines known to induce retinal toxicity (e.g. tamoxifen) or QT interval prolonging agents.
• Known congenital or documented acquired QT prolongation.

Other

• Known maculopathy of the eye
• Pregnant women and breastfeeding mothers are excluded due to unknown impact on embryos or infants
• Uncorrected hypokalemia and/or hypomagnesemia
• Patients with known central nervous system metastases.

• Patients must have pathologically confirmed advanced metastatic pancreatic adenocarcinoma or poorly differentiated pancreatic adenocarcinoma that is amenable to tumour biopsy.
• Patients have received at least one line of systemic therapy for metastatic disease and not be amenable to surgical resection.
• Patients must have measurable disease by RECIST 1.1 criteria.
• Age ≥18 years.
• ECOG performance status ≤ 1
• Patients must have normal organ and marrow function as defined below: a. Serum creatinine ≤ 1.5 x ULN. b. Adequate hepatic function defined by: o total bilirubin level ≤ 1.5 × ULN, o an AST, level ≤ 2.5 × ULN, and an ALT level ≤ 2.5 × ULN (or, for subjects with documented metastatic disease to the liver, AST and ALT levels ≤ 5 × ULN) c. Hematological eligibility parameters: o Absolute Neutrophil count ≥ 1.5 x 109/L o Platelet count ≥100 x109/L o Hemoglobin ≥ 9 g/dL
• Ability of subject to understand and the willingness to sign a written informed consent document.
• Women of child-bearing potential or sexually active males must agree to use highly effective contraceptive measures. This applies from starting treatment until at least 16 weeks after the last study drug administration. The investigator or a designated associate is required to advise the patient how to achieve an adequate birth control. Highly effective contraception is defined in the study as methods that achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include: I. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal). II. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable and implantable). III. Intrauterine device (IUD). IV. Intrauterine hormone-releasing system (IUS). V. Bilateral tubal occlusion. VI. Successfully vasectomised partner. VII. Sexual abstinence.